Literature DB >> 15132729

The associations between plasma adiponectin, ghrelin levels and cardiovascular risk factors.

K M Choi1, J Lee, K W Lee, J A Seo, J H Oh, S G Kim, N H Kim, D S Choi, S H Baik.   

Abstract

OBJECTIVE: Ghrelin is a recently discovered peptide, which is produced primarily in the stomach. This orexigenic peptide participates not only in the induction of mealtime hunger but also in long-term body weight regulation and energy homeostasis. Adiponectin is a protein secreted by adipocytes, and has been proposed to mediate obesity-related insulin resistance. Moreover, concentrations of adiponectin are reduced in individuals with obesity, insulin resistance and cardiovascular disease. However, human data are sparse about the direct relationship between adiponectin, ghrelin and cardiovascular risk factors including insulin resistance.
DESIGN: Three hundred and thirty-eight elderly Korean women (mean age+/-s.d., 72.3+/-5.5 years) were included in the present study.
METHODS: Plasma ghrelin and adiponectin levels were measured by RIA. Anthropometric measurements were taken and a 75 g oral glucose tolerance test performed. Fasting insulin and lipid profile were measured and insulin resistance was determined using the homeostasis model assessment insulin resistance index (HOMA-R) and the quantitative insulin sensitivity check index.
RESULTS: Plasma adiponectin levels were negatively correlated with central obesity indices such as waist circumference (r=-0.27, P<0.001) and waist-to-hip ratio (WHR) (r=-0.32, P<0.001), and with insulin resistance indices such as fasting insulin (r=-0.17, P=0.004) and HOMA-R (r=-0.13, P=0.035). Plasma ghrelin levels were negatively correlated with WHR (r=-0.12, P=0.03), but plasma adiponectin and ghrelin levels were not correlated (r=0.03, P=0.66). Multiple regression analysis showed that adiponectin was associated with WHR, fasting insulin and fasting glucose levels. When ghrelin was used as a dependent variable, only WHR remained in the final fitted model.
CONCLUSION: Fasting plasma adiponectin and ghrelin levels were found to be associated with central obesity or insulin resistance. However, plasma adiponectin and ghrelin concentrations were not associated with each other in elderly Korean women.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15132729     DOI: 10.1530/eje.0.1500715

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  13 in total

1.  Changes in ghrelin and asymmetrical dimethylarginine in obese Mexican adolescents after six-month lifestyle intervention.

Authors:  Fengyang Huang; Blanca Estela del-Río-Navarro; José Alfredo Pérez Ontiveros; Eliseo Ruiz-Bedolla; Efraín Navarro-Olivos; Santiago Villafaña; Guadalupe Bravo; Enrique Hong
Journal:  Endocrine       Date:  2012-09-29       Impact factor: 3.633

Review 2.  Inflammation, insulin resistance, and obesity.

Authors:  Patrizia Ferroni; Stefani Basili; Angela Falco; Giovanni Davì
Journal:  Curr Atheroscler Rep       Date:  2004-11       Impact factor: 5.113

3.  Alanine aminotransferase decreases with age: the Rancho Bernardo Study.

Authors:  Mamie H Dong; Ricki Bettencourt; Elizabeth Barrett-Connor; Rohit Loomba
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

4.  The effects of macronutrient intake on total and high-molecular weight adiponectin: results from the OMNI-Heart trial.

Authors:  Edwina H Yeung; Lawrence J Appel; Edgar R Miller; W H Linda Kao
Journal:  Obesity (Silver Spring)       Date:  2009-10-29       Impact factor: 5.002

5.  Ghrelin and obestatin levels in severely obese women before and after weight loss after Roux-en-Y gastric bypass surgery.

Authors:  Christian L Roth; Thomas Reinehr; Gerit-Holger Schernthaner; Hans-Peter Kopp; Stefan Kriwanek; Guntram Schernthaner
Journal:  Obes Surg       Date:  2008-06-03       Impact factor: 4.129

6.  Circulating ghrelin, leptin, and soluble leptin receptor concentrations and cardiometabolic risk factors in a community-based sample.

Authors:  Erik Ingelsson; Martin G Larson; Xiaoyan Yin; Thomas J Wang; James B Meigs; Izabella Lipinska; Emelia J Benjamin; John F Keaney; Ramachandran S Vasan
Journal:  J Clin Endocrinol Metab       Date:  2008-05-20       Impact factor: 5.958

7.  A meta-analysis of genome-wide association studies for adiponectin levels in East Asians identifies a novel locus near WDR11-FGFR2.

Authors:  Ying Wu; He Gao; Huaixing Li; Yasuharu Tabara; Masahiro Nakatochi; Yen-Feng Chiu; Eun Jung Park; Wanqing Wen; Linda S Adair; Judith B Borja; Qiuyin Cai; Yi-Cheng Chang; Peng Chen; Damien C Croteau-Chonka; Marie P Fogarty; Wei Gan; Chih-Tsueng He; Chao A Hsiung; Chii-Min Hwu; Sahoko Ichihara; Michiya Igase; Jaeseong Jo; Norihiro Kato; Ryuichi Kawamoto; Christophor W Kuzawa; Jeannette J M Lee; Jianjun Liu; Ling Lu; Thomas W McDade; Haruhiko Osawa; Wayne H-H Sheu; Yvonne Teo; Swarooparani Vadlamudi; Rob M Van Dam; Yiqin Wang; Yong-Bing Xiang; Ken Yamamoto; Xingwang Ye; Terri L Young; Wei Zheng; Jingwen Zhu; Xiao-Ou Shu; Chol Shin; Sun Ha Jee; Lee-Ming Chuang; Tetsuro Miki; Mitsuhiro Yokota; Xu Lin; Karen L Mohlke; E Shyong Tai
Journal:  Hum Mol Genet       Date:  2013-10-08       Impact factor: 6.150

8.  Adipocytokine and ghrelin levels in relation to cardiovascular disease risk factors in women at midlife: longitudinal associations.

Authors:  R P Wildman; P Mancuso; C Wang; M Kim; P E Scherer; M R Sowers
Journal:  Int J Obes (Lond)       Date:  2008-01-08       Impact factor: 5.095

9.  Relationships between acylated ghrelin with growth hormone, insulin resistance, lipid profile, and cardio respiratory function in lean and obese men.

Authors:  Hasan Matin Homaee; Fatah Moradi; Mohammad Ali Azarbayjani; Maghsoud Peeri
Journal:  J Res Med Sci       Date:  2011-12       Impact factor: 1.852

10.  Low serum adiponectin concentrations are associated with insulin sensitivity independent of obesity in Sudanese subjects with type 2 diabetes mellitus.

Authors:  Moawia Abdelgadir; Anders F Karlsson; Lars Berglund; Christian Berne
Journal:  Diabetol Metab Syndr       Date:  2013-03-13       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.